8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
1/68
Presented by
DR LADIPO T.A
DEPARTMENT OF RADIOTHERAPY
NHA
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
2/68
Breast cancer is one of the major diseases ofpublic health importance.
Worldwide it is the most common cancerin women. It affects about 1% of male
population. Breast cancer is second only to lung cancer in
mortality world wide.Incidence varies greatly around the world,
being lower in less-developed countriesand greatest in the more-developedcountries.
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
3/68
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
4/68
A TIP OF THE ICEBERG
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
5/68
Breast cancer is the leading cause of death inwomen aged 45-50yrs.
The 5yr survival is 60% overall but is greaterthan 80% for early disease.(Hemant singal etal,2009)
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
6/68
It is rarely found before the age of 25yrsexcept in certain familial cases.
Rates are high in USA,Scotland and westernEurope.
Estimated new cases and deaths from breastcancer in the United States in 2008:New cases: 182,460 (female); 1,990 (male)
Deaths: 40,480 (female); 450 (male)(Breast cancer.org.)
At U.C.H diagnosed in 22yr old female.
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
7/68
Women in the US have 1 in 8 (12.5%) lifetimechance of developing invasive breast cancerand 1 in 35 (3%) chance of breast cancercausing their death.
Breast cancer affects African-Americanwomen less than white women.
Black women are less likely to get the
disease, but are more likely to die from it.Black women also get the disease at youngerage than white women.
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
8/68
The rate of breast cancer is very low in Japan,India and some areas of Africa .
Its the most common cancer in Nigeriaaccounting for 29.7% of 818 cancercases(Ibadan cancer registry).
The peak age incidence in Nigerian women isabout a decade earlier than in Caucasians.
It was estimated that between 7-10 thousandnew cases of breast cancer developed inNigeria in 2005.(Adebamowo et al).
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
9/68
Somatic mutations theory postulates theaccumulation of mutations in somatic genesthat progressively deregulate normal breastbehavior,
The cell is believed to be the epithelial celllining the terminal duct lobular unit,
Several processes predispose to mutation
including exposure to mutagens e.g.radiation, mitogens such as estrogen,
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
10/68
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
11/68
Mitogens are thought to predispose tomalignant transformation by increasing therisk of unrepaired DNA replication errorsduring stimulated cell division.
Over expression of certain genes e.g.epidermal growth factor, HER-2, is associatedwith high nuclear grade,(25% of all B.C)
Others are p53(the guardian of the genome),cowden syndrome(PTEN),Ataxiatelegiectasia(ATM)
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
12/68
Inheritance of high penetrance dominantmutations account for 5-10% of breast ca andtypically presents with a strong family historye.g. BRCA1&2 genes.
The biochemical basis of the cellular effect isa repair defect, rendering the genome proneto mutation a state referred to as genomicinstability.(Treatment of cancer 4th edition-Pat Price&Karol Sikora).
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
13/68
MAJORo Female gender(M:F 1:100)o Increase age(late 30s-0.07% risk,70s-0.44%)
o western culture(dietary and enviromental)
o Family history( 1.7% and 1.4% in 1st & 2nddegree relatives respectively)
o Benign breast dx (proliferative benign dxs)
o Radiation( children & adolescent)
o Prior diagnosis of breast ca(10-15% incontralateral dx risk)
o Mutation in BRCA 1% 2( 64% & 45% respectively)
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
14/68
MODERATEo Early menarche/ late menopause
o Nulliparity / delayed full term preg.
o
High socioeconomic statuso Country of residence
o Alcohol intake
o Obesity
o Prior diagnosis of uterine, ovarian, or colonicca.
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
15/68
OTHERS;o Oral contraceptive pills
o Hormone replacement therapy
o
High density breast mammograpyo High fat diet,
o Drugs-antihypertensive(Rauwolfia cpds)
(Cancer medicine 4th edition-Holland et al).
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
16/68
Some risk factors associated with bilateraldisease are;
o Young age at first onset.
o Positive family history.
o Multicentric disease in ipsilateral breast.
o Invasive lobular subtype
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
17/68
Considering the combination of risk factors in anindividual ,it is possible to predict his annual andlife time risk of breast ca.
Gail et al uses these epidemiological factors to
derive a model for predicting breast ca risk. Commonly used by Gail are;
o Age at presentation
o Nos of 1st degree relativeso Age at 1st birth
o Age at menarche
o No of biopsy & result
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
18/68
Based on the model people with high risk ofdeveloping breast ca.are councel to considereither prophylactic tamoxifen use orprophylactic surgery.
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
19/68
TAMOXIFEN ;o Reduce the incidence of invasive & non
invasive by 49% & 50% respectively(Perez etal)
o Decreases the incidence of contralateralbreast ca(NSABP)
o Individuals with high risk detected using Gail
model who uses tamoxifen for 5yrs, haveincrease 5yrs free dx rate(Perez et al)
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
20/68
PROPHYLACTIC SURGERY; Results shows 89.5% decrease in risk for
those that had this procedure(Mayo clinic1993)
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
21/68
Lower age at first childbirth (less than 24 yearsmaternal age),
Multiparity (about 7% lowered risk per child),
Breastfeeding (4% per breastfeeding year, with
an average relative risk around 0.7%) Breast ca risk decreased by 7% for every
12months of breastfeeding
Adebamowo CA , Campbell O B , Adenipekun A ,et al ( Br J Cancer 2008)
In addition, exercising three times a week for onehour each has been found to lower breast cancerby up to 40%
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
22/68
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
23/68
The (2003) World Health Organization (WHO)classification of tumors of the breastrecommends the following pathological typesInvasive breast carcinomas
Invasive ductal carcinoma Most are "not otherwise specified" The remainder are given subtypes:
Mixed type carcinoma
Pleomorphic carcinoma
Carcinoma with osteoclastic giant cells
Carcinoma with choriocarcinomatous features
Carcinoma with melanotic features
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
24/68
Invasive lobular carcinoma Tubular carcinoma
Invasive cribriform carcinoma
Medullary carcinoma Mucinous carcinoma and other tumors with
abundant mucin Mucinous carcinoma
Cystadenocarcinoma and columnar cell mucinouscarcinoma
Signet ring cell carcinoma
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
25/68
Neuroendocrine tumors Solid neuroendocrine carcinoma (carcinoid of the
breast)
Atypical carcinoid tumor
Small cell / oat cell carcinoma Large cell neuroendocrine carcioma
Invasive papillary carcinoma
Invasive micropapillary carcinoma
Apocrine carcinoma
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
26/68
Metaplastic carcinomas Pure epithelial metaplastic carcinomas
Squamous cell carcinoma
Adenocarcinoma with spindle cell metaplasia
Adenosquamous carcinoma Mucoepidermoid carcinoma
Mixed epithelial/mesenchymal metaplasticcarcinomas
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
27/68
Lipid-rich carcinoma Secretory carcinoma
Oncocytic carcinoma
Adenoid cystic carcinoma Acinic cell carcinoma
Glycogen-rich clear cell carcinoma
Sebaceous carcinoma
Inflammatory carcinoma
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
28/68
Sarcomas:-Angiosarcoma
-Liposarcoma
-Rhabdomyosarcoma-Leiomyosarcoma
-Fibrosarcoma
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
29/68
Precursor lesions Lobular neoplasia
lobular carcinoma in situ(LCIS)
Intraductal proliferative lesions Usual ductal hyperplasia
Flat epithelial hyperplasia
Atypical ductal hyperplasia
Ductal carcinoma in situ(DCIS)
Microinvasive carcinoma
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
30/68
Intraductal papillary neoplasms Intraductal papillary carcinoma
Intracystic papillary carcinoma
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
31/68
Tumors of the nipple Paget's disease of the nipple
Malignant lymphoma Metastatic tumors Tumors of the male breast Carcinoma
In situ
Invasive
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
32/68
Multiple tumor grading systems have beenproposed. The Scarff-Bloom-Richardsonclassification system utilizes mitotic index,differentiation, and pleomorphism, each with
scores of 1 to 3. Scores of 3 to 5 are welldifferentiated, 6 to 7 moderatelydifferentiated, and 8 to 9 poorlydifferentiated. This system is commonlyemployed and has been shown to be ofindependent prognostic significance
Nottingham model.
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
33/68
Actual field size 150 X 100 microns) Arrow heads show themyoepithelial cells apposed to the basal lamina. Ductal cells(short arrows) are partly overlapping in this section but form asingle cell layer above the myoepithelium. Long thin arrows showseveral of the periductal fibroblasts. These have characteristiclong pointed nuclei, they show a typical orientation of their long
axis parallel with the basal lamina, and they appear inactive(heterochromatic nuclei) in this duct. Mature collagen with a wavy
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
34/68
Figure 28: DCIS with invasive ductal carcinoma, high magnification. (Actual field size 360 X 240 microns) This is from the same patient as Figure 27, but from a
different area of the biopsy. The arrow heads outline a focus of intraductal carcinoma. This DCIS hasa smooth outer contour, and the extracellular matrix has a normal concentric arrangement aroundthis duct. The fibroblasts around this duct (thin arrows) are thin, arranged in the normal parallelorientation to the duct, and they appear inactive since they do not have much euchromatin ornucleoli. In contrast, the other ductal cells are all "invasive" and show a ragged contour without anorganized concentric wrap of extracelluar matrix around them. The fibroblasts near the invasiveductal cells appear highly active (thick arrows) with open chromatin and nucleoli. The products ofthe active fibroblasts include bubbly bluish mucopolysaccharides and young finely fibrillar collagen.To diagnose invasion, it is often essential to look at the non-neoplastic stromal cells.
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
35/68
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
36/68
(T) -Primary TumorTx - Primary tumor cannot be assessed.
T0 - No evidence of primary tumor.
Tis - Carcinoma in situ.Tis(DCIS) - Intraductal Carcinoma in situ.
Tis(LCIS) - Lobular Carcinoma in situ.
Tis(Paget's) - Paget's disease of the nipple with
no tumor.
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
37/68
T1 - Tumor 2cm or less in its greatestdimension. T1mic - Microinvasion 0.1cm or less in greatest
dimension. T1a - Tumor more then 0.1cm but not more than
0.5cm in its greatest dimension. T1b - Tumor more than 0.5cm but not more than
1.0cm in its greatest dimension. T1c - Tumor more than 1.0cm but not more than
2.0cm in its greatest dimension. T2 - Tumor more than 2.0cm but not more
than 5.0cm in its greatest dimension.
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
38/68
T3 - Tumor more than 5cm in its greatestdimension.
T4 - Tumor of any size with direct extensionto (a) chest wall or (b) skin as described
below: T4a - Extension to chest wall.
T4b - Oedema (including peau d'orange) orulceration of the breast skin, or satellite skin
nodules confined to the same breast. T4c - Both T4a and T4b.
T4d - Inflammatory breast cancer.
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
39/68
Lymph NodeThere are four lymph node classification
values (N0, N1, N2 or N3) which depend onthe number, size and location of breast
cancer cell deposits in lymph nodes.
o Nx - regional lymph nodes cannot beassessed. Perhaps due to previous removal.
o
N0 - no regional lymph node metastasis.
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
40/68
o N1 - metastasis to movable regional axillarylymph nodes on the same side as the affectedbreast.
o N2 - metastasis to fixed regional axillary lymph
nodes, or metastasis to the internal mammarylymph nodes, on the same side as the affectedbreast.
o N3 - metastasis to supraclavicular lymph nodes
or infraclavicular lymph nodes or metastasis tothe internal mammary lymph nodes withmetastasis to the axillary lymph nodes
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
41/68
MetastasesThere are two metastatic classification
values (M0 or M1) which depend on thepresence or absence of breast cancer cells in
locations other than the breast and lymphnodes (so-called distant metastases, e.g. tobone, brain, lung).
o M0 no distant metastasis
o M1 distance metastasis is present
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
42/68
STAGE-1 Tumor confined to breast and notattached to underlying muscle.
no axillary LN.
STAGE-2 As in stage 1,but axillary LN are
involved but mobile. STAGE-3 I-Skin involvement beyond periphery
of tumor or
ll-tumor attached to underlying
muscle lll-Axillary LN are mobile or fixed.
There are no distant metastasis.
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
43/68
STAGE 4 l-Lymphatic spread is beyond theipsilateral axilla.
ll-Distant blood-bornemetastasis
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
44/68
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
45/68
STAGE 5yr survival(%) 10yr survival(%)0 99 95
1 97 88
II 83 66
III 54 36
IV 16 7
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
46/68
PAINLESS BREAST LUMP. .BLOOD STAINED NIPPLE DISCHARGE(DUCT
CA)
RETRACTION OF THE NIPPLE
LYMPHEDEMA OF THE BREAST&/ARM.
ECZEMA OR DERMATITIS OF THEAREOLA(PAGETS DX)
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
47/68
METASTASES;o Pulmonary- Cough, dyspnea.
o Bone deposit- bone pain, pathologic #, bonyswellings of skull, ribs, clavicle.
o Cord compression from vertebra deposits or# may result in paraplegia.
o Liver -hepatomegaly,ascites.
o Brain metastasis-features of raised ICP.
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
48/68
FIBROADENOMA CYST
GALATOCELE
CHRONIC BREAST ABSCESS
TRAUMATIC FAT NECROSIS
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
49/68
LOCAL INVASION LYMPHATIC SYSTEM
BLOOD STREAM
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
50/68
Most common site-upper outer quadrant. Commoner on the left breast
Unusual for both to occur simultaneously
The growth travels along the duct
Breaks through the basement mmb. of ductinvading adjacent duct, fascia, mammary fat,spreading through breast lymphatics to
peripheral lymphatics.
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
51/68
Common route, first to the axillarynodes(increases with tumor size)
Then to other nodes-internal mammary,supraclavicular LN,
Then vascular invasion by tumor &haematogenous metastasis.
(Carlos Perez & Co prin. & prac. of Radiology
oncology 3
rd
ed)
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
52/68
BREAST SELF EXAMINATION CLINICAL BREAST EXAMINATION
MAMMOGRAPHY
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
53/68
Starting at 40yrs,yearly mammograpy shouldbe done.
Clinical examination by a physician every 3yrsfor those in 20s and 30s and annually for
those with 40yrs and above. Breast self examination monthly starting with
women in there 20s.
Those with high risk(family history,|)shouldhave earlier mammograpy starting at25yrs.US &MRI can also be done.
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
54/68
HISTORY-menstrual status, parity, family hx , PHYSICAL exam- breast, axillary LN (size,
mobility, no), supraclavicular fossa,abdomen, spine.
Excisional biopsy if lump is small
Otherwise incisional biopsy
Core needle biopsy
Histological diagnosis ER/PR and HER2/neu
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
55/68
RADIOLOGIC studies-mammography,ultrasound, CXR, abdominopelvic USS, Bonescan, MRI, CT scan.
LAB studies- FBC, E/U & Cr, alkaline
phosphatase, LFT. Urinalysis.
Tumour markers.
Oncogene assay- BRCA 1 & 2, HER-2
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
56/68
INTRINSIC:o Axillary nodes(1-3 ,73% 5yr survival rate)o Tumor size(
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
57/68
o Presence of multiple primary tumor(multicentricity).
o Proliferative rate (High)- mitotic index,thymidine labeling index, s-phase fraction-
poor prognosis.o Over expression of her-2, CA-15-3, CA27-
29, Epidermal growth factor
o Lymphovascular invasion(recurrence rate for
LVI+VE -38%,LVI-VE -22%)o P53-over expression-poor prognosiso Tumor location medial tumors worst prog.
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
58/68
EXTRINSIC Factors:o Age-worse with younger age(ER-ve
status,high grade dx)
o Race-Black women,advanced stages.
o Obesity-Greater risk of reoccurrence.
o Smoking??
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
59/68
Rare occurrence. Incidence
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
60/68
Same histologic subtypes of invasive cancer. More rapidly infiltrates to become attached to
overlying skin and thoracic wall.
Distant metastasis to lungs,brain,bone&liver
are common.
Presents in a more advanced stage in men.
Estrogen receptor tumor is more predominant
in males.
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
61/68
Among women with breast ca 1-2% arepregnant. No evidence that pregnancy is associated with
either the development or progression of
breast ca. Prognosis is related to stage,worse prognosis
because;
-Delayed diagnosis
-Reluctance with use of mammograpy -Changes in the breast during pregnancy
makes cancer difficult to detect.
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
62/68
This is a type of breast cancer that is clinicallynegative for ER/PR and HER-2 proteins. Constitute of 15% of all breast cancer in
USA(medscape 2009) Its more common in;o Carriers of BRCA-1 gene mutationo Young womeno African-American women HIGHEST RISK young and african-American It is characterized by its unique molecular profile,
aggressive behavior, distinct patterns ofmetastasis, and lack of targeted therapies.
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
63/68
UP to 50% of breast cancer patient in Africahave this disease.Although;
o Data collection?
o Screening tools?
(Lisa carey et al,medscape 2009)
TNBC is a traumatic diagnosis to both theclinician and patient as it doesnt respond to
conventional treatment.
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
64/68
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
65/68
As opposed to other breast cancer types,itsresponse to chemotherapy is better withPlatinum compound(Effective for BRCA-1disease) than with anthracyclines and taxanes
Screening for early detection is a problem dueto poor access to the facilities especially inAfrica due to poverty
Also some with high risk are too young forstandard screening
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
66/68
More researches are on the way to unveilpromising treatment modalites;o Antiangiogenic agents e.g intergroup
E5103(early disease)
o PARP (ADP-ribose polymerase) inhibitorso EGFR, C-KIT inhibitorso MAP-kinase inhibitorso Mtor inhibitors
o -VEGFo HER/1
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
67/68
8/3/2019 Breast Carcinoma,Pathology (Dr Ladipo)
68/68
THANK YOU
Top Related